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a b s t r a c t
Neuropathic pain still present a major diagnostic and therapeutic challenge despite con-
siderable progress in understanding of its mechanisms and publication of number of studies
which assessed the efﬁcacy and safety of drugs used in the symptomatic treatment. In
practice, it is diagnosed less frequently than recognised in the epidemiological studies, and
many patients do not achieve satisfactory outcomes of treatment. A multidisciplinary team
of Polish experts, commissioned by the Polish Association for the Study of Pain and the
Polish Neurological Society, has reviewed the literature on neuropathic pain, with special
focus on the published international recommendations, and formulated recommendations
on neuropathic pain diagnosis and treatment, in accordance with the principles of evidence-
based medicine. The paper presents also background information on the neuropathic pain
deﬁnition, epidemiology, pathomechanism and method of assessment. The diagnosis of
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including special assessment of the somatosensory system. First-line drugs used in phar-
macological management of neuropathic pain are: tricyclic antidepressants, serotonin and
norepinephrine reuptake inhibitors, gabapentin, pregabalin, opioids and lidocaine patches.
# 2014 Polish Neurological Society. Published by Elsevier Urban & Partner Sp. z o.o. All
rights reserved.
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Neuropathic pain is a unique type of pain characterised by
speciﬁc clinical presentation and low efﬁcacy of analgesics and
anti-inﬂammatory agents. Despite relatively high prevalence,
it is rarely diagnosed, and even more rarely adequately and
effectively treated. In the last years several evidenced-based
recommendations on the diagnosis and management of this
type of pain have been published. They include recommenda-
tions of expert groups commissioned by international medical
associations, such as the International Association for the
Study of Pain (IASP) and the European Federation of Neuro-
logical Societies (EFNS), as well as recommendations of
national research associations in countries such as Australia,
France, Canada and South Africa. Some of these recommen-
dations have been presented previously to Polish physicians
[1,2]. Differences related to the health care system and drug
availability on the Polish pharmaceutical market necessitate
adapting the recommendations to Poland-speciﬁc conditions.
The review of literature and recommendations was the
initiative of physicians and researchers gathered in the
Commission of Pain Pathophysiology of the Committee of
Neurological Sciences of the Polish Academy of Sciences and
followed by formation of the expert group representing the
Polish Association for the Study of Pain and the Polish
Neurological Society. At successive meetings, the experts
reviewed the literature on neuropathic pain, paying special
attention to the published review papers and recommenda-
tions, as well as results from randomised clinical trials. The
review was focused on the diagnosis and management of
neuropathic pain and its speciﬁc syndromes, and comple-
mented with neuropathic pain deﬁnition, epidemiology,
pathomechanism and assessment methods. The paper was
divided into two parts: part one, which is being presented now,
focused on the overview of neuropathic pain assessment and
treatment, and part two, which will be published in the next
issue of the journal, focused on the most common neuropathic
pain syndromes.
The recommendations are addressed primarily to physi-
cians of different specialities, who diagnose and treat chronic
pain in their everyday practice. We hope that the publication
will be helpful to the physicians and facilitate improvement of
the pain management standards in Poland.
2. Deﬁnition of neuropathic pain
Neuropathic pain is not a disease, but a syndrome manifested
by more or less speciﬁc symptoms and signs, caused by a rangeof different disease and lesions. According to the ﬁrst
deﬁnition appeared in the Classiﬁcation of Chronic Pain
published by IASP in 1994 [3], neuropathic pain is the ‘‘pain
initiated or caused by a primary lesion, dysfunction, or
transitory perturbation of the peripheral or central nervous
system’’. The deﬁnition has been widely used for many years,
despite critical comments made by many researchers. The
most recent deﬁnition proposed by experts and approved by
the Task Force on Taxonomy of the IASP is as follows: ‘‘pain
arising as a direct consequence of a lesion or disease affecting
the somatosensory system’’ [4].
Neuropathic pain may arise as a direct consequence of a
lesion or disease of the peripheral (peripheral neuropathic pain)
or central (central neuropathic pain) somatosensory nervous
system [5]. The cause of neuropathic pain may be known, e.g.
infection, injury or metabolic disorder, or unknown. The same
lesion or disease may cause the development of neuropathic, as
well as somatic or even psychogenic pain. Therefore, neuro-
pathic pain may be the only one of the component of a patient's
acute or chronic pain syndrome.
Deﬁnite diagnosis of neuropathic pain is not always
possible. The authors of the new criteria of neuropathic pain
deﬁned also the four criteria for grading of certainty of
neuropathic pain diagnosis, as follows:
1. Pain with a distinct neuroanatomically plausible distribu-
tion.
2. A history suggestive of a relevant lesion or disease affecting
the peripheral or central somatosensory system.
3. The presence of negative or positive neurologic signs
concordant with the distribution of pain in neurological
examination or in the more objective conﬁrmatory tests
(quantitative sensory testing, laboratory tests).
4. Demonstration of the relevant lesion or disease by at least
one conﬁrmatory test.
Using these criteria neuropathic pain can be classiﬁed as
deﬁned (all criteria present), probable (1 and 2, plus either 3
or 4) or possible (1 and 2, without conﬁrmatory evidence from
neurological examination and conﬁrmatory tests) [4].
3. Epidemiology of neuropathic pain
Only few epidemiological studies of neuropathic pain have
been carried out and published as yet. They are difﬁcult to
make because of subjectivity of the sensation of pain, difﬁculty
setting apart neuropathic pain from complex pain syndrome
and lack of a widely approved standard tool for identifying
neuropathic pain.
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patients evidenced neuropathic pain in 8.2% of adult patients
having signiﬁcantly higher pain intensity than others [6]. The
French study in a randomly selected adult population using
the Douleur Neuropathique 4 Questions (DN4) questionnaire,
identiﬁed neuropathic pain in 6.9% of 23,712 examined
persons [7]. The most common risk factors for neuropathic
pain included: female sex, elderly age, lower level of education
and living in a rural area. Neuropathic pain was associated
with worse health, i.e. compromised physical, mental and
social well-being [7–11].
4. Pathomechanism of neuropathic pain
Neuropathic pain is a result of many processes related to
inefﬁcient repair capabilities and adaptation to a lesion or
disease of the nervous system. Neuronal overexcitability,
which characterises all neuropathic pains, is not a manifesta-
tion of one mechanism but rather results from a combination
of many factors which, having accumulated, determine the
degree and type of overexcitability in individual patients and
in individual pain syndromes.
The best known pathomechanisms responsible for the
development of neuropathic pain can be divided into at least
three groups. The ﬁrst one includes changes in electrophys-
iological properties of the cellular membrane of the ﬁrst
sensory neuron, which include both changes in nociceptor
excitability (lowered excitability threshold, possibility of
spontaneous excitations) and changes in the release of
neurotransmitters. The group also includes changes in gene
expression in neuronal cell body. The second group of
potential mechanisms underlying neuropathic pain is
related to changes in impulse processing in the dorsal
horns of the spinal cord. Many researchers emphasise the
special role of intensiﬁcation of glutamatergic transmission,
dysfunction of the descending inhibitory systems in the
spinal cord, microglial activation and changes in neuronal
morphology consisting in, among others, rearrangement of
synaptic junctions. The third group includes disorders in
higher levels of the central nervous system, such as
disturbed balance between the activity of ascending excit-
atory systems and descending inhibitory (antinociceptive)
systems. Furthermore, the autonomic nervous system
dysfunction may be also involved in the development of
neuropathic pain [12,13].
5. Clinical assessment of a patient with
neuropathic pain
Examination of a patient with neuropathic pain begins with
taking detailed medical history including the duration and
characteristics of pain (its intensity, changes over time,
sensation types, etc.), its relation on other factors, accompa-
nying symptoms and response to treatment.
Medical history should reveal whether or not pain
characteristics and location are consistent with diagnostic
criteria for neuropathic pain and the relevant lesion or disease
of the nervous system might be a probable cause of pain.The second step is physical examination, both general and
neurological, focused in particular on somatosensory system
assessment. The examination should include the sensation of
touch, pain (pinprick), temperature (warmth and cold) and
vibration, as well as temporal summation. The area where the
complaints are most intense should be examined and
compared with the opposite side. The aim of the examination
is to identify negative (loss of function) and positive symptoms
(e.g. hyperalgesia, allodynia) related to one or several types of
sensation most likely to have resulted from a lesion or disease
of the somatosensory nervous system.
Further diagnostic evaluation may be performed to docu-
ment the presence of a speciﬁc disease of the nervous system
(e.g. brain imaging documenting past stroke in patients with
central pain) or a lesion of the sensory pathways in the pain
area (e.g. skin biopsy documenting loss of small ﬁbres in the
case of neuropathy) [14].
6. Quantitative sensory testing and laboratory
assessment
Quantitative sensory testing (QST) using appropriate, usually
relatively simple tools, is a method complementing the
neurological examination. Measuring the threshold of sensory
perceptions in response to external stimuli of controlled
intensity, both increasing and decreasing, it allows compara-
tive assessment of positive sensory symptoms, such as
mechanical and thermal allodynia and/or hyperalgesia. The
assessment of the sensory perception over time may predict
and monitor treatment outcomes.
Pain assessment may also involve laboratory tests, such as
nerve conduction study (NCS), somatosensory-evoked poten-
tial (SEP), laser-evoked potential (LEP) or intraepidermal nerve
ﬁbres (IENF) density quantiﬁcation in a skin biopsy specimen.
However, these techniques require an appropriate equipment
and experience of the examiners; they are performed in only
few clinical research centres.
Clinical (neurological), quantitative and laboratory meth-
ods employed for the assessment of speciﬁc sensation types,
in relation to the types of nerve ﬁbres involved in nociception,
are presented in Table 1 [4,14].
7. Neuropathic pain screening scales
The screening scales have been developed for epidemiological
studies and can be of use in identifying neuropathic pain or the
presence of a clear neuropathic component in the patient's
pain syndrome. They may be used if medical history or
physical examination reveal typical signs of neuropathic pain.
Each scale has its own sensitivity and speciﬁcity. The most
widely used screening scales include:
 Leeds Assessment of Neuropathic Symptoms and Signs (LANSS).
The scale comprises 5 questions about pain and 2 items
related to clinical examination. The scale speciﬁcity is 85%
and sensitivity 80%. The score of 12/24 means pain of
predominantly neuropathic origin [14–16]. The scale has
been validated in a number of centres [14].
Table 1 – Clinical, quantitative and laboratory sensory testing methods [4,14].
Fibre type Sensation type Testing method
Clinical QST Laboratory tests
Ab Touch Cotton wool ball von Frey ﬁlaments NCS, SEP
Vibration Tuning fork Vibrameter NCS, SEP
Ad Pain – pin prick Stick Weighted needles NCS, LEP, IENF density
quantiﬁcation in the
skin biopsy
Cold Thermoroller Thermotest or other tool
for assessing reaction to
changing temperature
No tool
C Warmth Thermoroller Thermotest or other tool
for assessing reaction to
changing temperature
NCS, LEP, IENF density
quantiﬁcation in the
skin biopsy
Pain – burning No tool Thermotest or other tool
for assessing reaction to
changing temperature
NCS, LEP, IENF density
quantiﬁcation in the
skin biopsy
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7 questions about symptoms and 3 items related to clinical
examination. The scale speciﬁcity is 83% and sensitivity 90%.
The score > 4/10 means pain of predominantly neuropathic
origin [14,17]. The scale has been validated in a number of
countries.
 Pain DETECT. The scale comprises 9 weighted questions
about symptoms. It does not include items related to clinical
examination. The scale speciﬁcity is 85% and sensitivity 80%.
The score > 19/38 means pain of predominantly neuropathic
origin [18].
 Neuropathic pain questionnaire (NPQ) comprises 12 questions,
10 of which are related to symptoms or sensory response,
and 2 are related to an emotional aspect. A short form of NPQ
comprises 3 questions about response to touch. The scale
speciﬁcity is 66% and sensitivity 74% [19].
8. Diagnosis of neuropathic pain –
recommendations
1. The diagnosis of neuropathic pain can be established by a
physician based on characteristic clinical presentation and
relation to a lesion or disease of the nervous system; in the
case of lack of experience in diagnosing neuropathic pain,
conﬁrmation by a relevant specialist or in a reference centre
is recommended.
2. The diagnosis of the neuropathic pain should be accompa-
nied by the level of its certainty.
3. If an aetiological factor is known, it should be included in
the diagnosis, e.g. diabetic neuropathic pain, post-herpetic
neuropathic pain, central post-stroke pain, or neuropathic
pain following spinal cord injury.
4. The screening tests are a useful diagnostic method, but
their results cannot be the only basis for the diagnosis of
neuropathic pain.
5. Pain assessment with laboratory tests is recommended in
dubious cases and only in centres that have relevant
experience.9. Management of neuropathic pain – review
of published recommendations
The ﬁrst evidence-based recommendations for pharmaco-
logical management of neuropathic pain in the form of
algorithm, were published by IASP experts in 2005 [20]. They
analysed 105 controlled studies and assessed the treatment
efﬁcacy using measures such as NNT (number needed to
treat – the number of patients that need to be treated for one
to beneﬁt, e.g. at least 50% relief in pain, compared with a
control in a clinical trial) and NNH (number needed to harm
– the number of patients need to be exposed to a risk-factor
over a speciﬁc period to cause harm in one patient that
would not otherwise have been harmed). In their opinion,
the efﬁcacy of tricyclic antidepressants (TCAs) and two
anticonvulsants (gabapentin and pregabalin) in neuropathic
pain are supported by the greatest number of studies. The
best measure of NNT in peripheral neuropathic pain, was
found for TCAs, followed by opioids and gabapentin and
pregabalin.
The second version of the same IASP experts' recommen-
dations appeared in 2007 in the form of guidelines [21]. The
authors proposed a four-step approach to the management of
neuropathic pain and speciﬁed drugs to be used as ﬁrst-line,
second-line and third-line of treatment.
The guidelines of a group of European experts from EFNS
appeared in 2006. There were related not only to the drugs'
efﬁcacy but also to data on the quality of life, the drugs' effect
on sleep and the impact of comorbidities [22]. The guidelines
concerned the most common neuropathic pain syndromes, i.e.
painful peripheral polyneuropathy (including diabetic poly-
neuropathy), post-herpetic neuralgia, trigeminal neuralgia
and central pain. The revised versions of the guidelines
appeared in 2010 [23–25].
In subsequent years, other recommendations were also
published by experts, e.g. from the French Society for the Study
and Treatment of Pain [26], Canadian Pain Society (2007) [27],
Australian Pain Society [28] and expert panel from South Africa
[29].
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of neuropathic pain as proposed by IASP experts in 2007 is
presented in Table 2.
Based on the level of evidence from randomised trials, the
following drugs are recommended by IASP experts for the ﬁrst-
line treatment of neuropathic pain [21]: TCAs (ﬁrst nortripty-
line and desipramine, which are unavailable in Poland, and
subsequently other TCAs: amitriptyline, imipramine, etc.),
serotonin and norepinephrine reuptake inhibitors (SNRIs;
venlafaxine and duloxetine), calcium channel a2-d ligands
(gabapentin and pregabalin) and topical 5% lidocaine patches.
Opioids (morphine, oxycodone, methadone, levorfanol
[levorfanol is unavailable in Poland; authors' note]) and tramadol
are recommended for the second-line treatment, although in
some clinical situations they may be used in the ﬁrst-line
treatment. Other drugs, which are recommended for the third-
line treatment, include other anticonvulsants (carbamaze-
pine, valproic acid, lamotrigine, oxcarbazepine, topiramate),
other antidepressants (bupropion, citalopram, paroxetine),
mexiletine, dextromethorphan and topical capsaicin.
Based on a similar review of literature in accordance with
the principles of evidenced based medicine (EBM), EFNSTable 2 – Stepwise management of neuropathic pain [21].
Step 1
 Assess pain and establish the diagnosis of neuropathic pain
(if uncertain about the diagnosis, refer to a specialist)
 Establish the cause of neuropathic pain
 Identify comorbidities (e.g. cardiac, renal or hepatic disease,
depression, gait instability) that might be relieved or
exacerbated by
neuropathic pain treatment
 Educate the patient (about the diagnosis, available treatment
and realistic expectations)
Step 2
 Initiate therapy of the disease causing neuropathic pain,
if applicable
 Initiate symptomatic treatment with the following
(ﬁrst-line) drugs:
– TCA or SNRI (duloxetine, venlafaxine)
– calcium channel a2-d ligand, either gabapentin or pregabalin
– topical lidocaine used alone or in combination with other
ﬁrst-line drugs in patients with localised peripheral
neuropathic pain
– Opioid analgesics or tramadol alone or in combination with
other ﬁrst-line drugs in patients with acute neuropathic pain,
neuropathic cancer pain or episodic exacerbation of
severe pain
 Evaluate patient for psychotherapy
Step 3
 Reassess pain and quality of life frequently
 If substantial pain relief (e.g. pain reduction to ≤3/10) and no
clinically signiﬁcant adverse effects, continue treatment
 If partial pain relief (e.g. pain remains ≥4/10) after an
adequate dose for adequate time, add a second ﬁrst-line drug
 If inadequate pain relief (e.g. <30% pain reduction) after an
adequate dose for adequate time, switch to an alternative
ﬁrst-line drug
Step 4
 If treatment with ﬁrst-line drugs is ineffective, consider
second- and third-line drugs or referral to a reference centreexperts developed recommendations for pharmacotherapy
of speciﬁc neuropathic pain syndromes. In painful diabetic
peripheral neuropathy they recommended gabapentin,
pregabalin, TCAs, duloxetine and venlafaxine for the ﬁrst-
line treatment, and opioids and tramadol for the second-line
treatment. In post-herpetic neuropathy, gabapentin, pregaba-
lin, TCAs and 5% lidocaine patches were recommended for the
ﬁrst-line treatment, while capsaicin and opioids for the second-
line treatment. In trigeminal neuralgia, carbamazepine and
oxcarbazepine are recommended for the ﬁrst-line treatment,
and surgery for the second-line treatment [30].
Neuropathic pain is often refractory to pharmacological
treatment, which is why other modalities, including interven-
tional ones, are used. In 2013, Dworkin et al. presented
recommendations for interventional modalities for the man-
agement of neuropathic pain [30]. The authors assessed
published systematic reviews, clinical trials and existing
guidelines on the use of interventional modalities in the
management of neuropathic pain. In none of the most
common pain syndromes (herpes zoster and post-herpetic
neuralgia, painful diabetic neuropathy and other peripheral
neuropathies, pain following spinal cord injury, post-stroke
pain, radiculopathy and failed back surgery syndrome [FBSS],
complex regional pain syndrome [CRPS], neuralgia and
trigeminal neuropathy) have strong recommendations for
interventional modalities been developed. Weak recommen-
dations in terms of efﬁcacy and safety are as follows: epidural
steroids for herpes zoster and radiculopathy and spinal cord
stimulation in patients with FBSS and CRPS type 1. Of the
interventional modalities used in patients with trigeminal
neuralgia, microsurgical decompression produced best and
most durable outcomes. However, the effectiveness of inter-
ventional modalities in the management of neuropathic pain
management is limited – partial relief is achieved in not more
than 40–60% of patients. The authors emphasise the fact that in
future the use of interventional modalities should undergo
scrutiny which should include documented randomised trials,
long-term follow-up and comparative ‘‘head-to-head’’ trials.
10. Pharmacologic management of
neuropathic pain
Drugs from the following drug classes have been proven
effective in the management of neuropathic pain:
 antidepressants,
 anticonvulsants,
 opioid analgesics and tramadol,
 topical drugs (lidocaine, capsaicin),
 NMDA receptor antagonists.
It should be emphasised that the documented effectiveness
applies to speciﬁc drugs and doses. Based on the published
data on the strength of evidence for their effectiveness, the
drugs are classed as ﬁrst-, second- and third-line drugs for the
treatment of neuropathic pain (IASP recommendation) or for
the treatment of speciﬁc neuropathic pain syndromes (EFNS
recommendations). First-line drugs available on the Polish
pharmaceutical market include:
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 SNRI (duloxetine, venlafaxine),
 calcium channel a2d ligands (pregabalin, gabapentin),
 lidocaine patch 5% – for localised peripheral neuropathic pain,
 carbamazepine and oxcarbazepine – for trigeminal neuralgia
only.
Treatment should be started with a ﬁrst-line drug, and the
dose should be gradually titrated upwards until a satisfactory
effect has been achieved. If the effectiveness is unsatisfactory
or adverse effects occur, another ﬁrst-line drug may be used or
added to the previously used drug from another drug class. If
the effect is still unsatisfactory, second-line or third-line drugs
can be used, alone or in combination, tailored to the individual
patient's needs. In the case of deﬁned contraindications or co-
existing diseases or symptoms, as well as the need for other
therapies, the treatment of neuropathic pain should also be
individually tailored [31].
The effectiveness of drugs used for the treatment of
neuropathic pain is often dose-dependent. The recommended
initial doses, their titration upwards, maximum doses and
precautions for use of ﬁrst-line drugs are presented in Table 3.
11. Antidepressants
Antidepressants are indicated for the treatment of neuropath-
ic pain, as well as, pain coexistent with depression (level 1Table 3 – Recommended doses, precautions for use and most 
treatment of neuropathic pain.
Drug Initial dose Dose titration 
Amitriptyline 25 mg at bedtime 25 mg, every 3–7
days
Duloxetine 30 mg 30 mg, every week 
Venlafaxine 37.5 mg once or twice
daily
75 mg, every week 
Pregabalin 75 mg twice daily 300 mg over 3–7 days 
Gabapentin 100–300 mg at bedtime
or 100–300 mg three
times daily
100–300 mg every 1–7
days
Lidocaine
patch 5%
Maximum 3 TTSs for
up to 12 h/day
Usually, no dose
up-titration is
required
Tramadol 50 mg once or twice
daily
50–100 mg every 3–7
days
Strong opioids
(morphine,
oxycodone,
methadone)
10–15 mg of morphine
every 4 h or other
opioids in equivalent
doses
Once the therapeutic
dose has been set,
converting a
controlled-release ora
form is recommendedaccording to EBM) [23]. Due to the inhibitory effect on serotonin
and norepinephrine reuptake, they increase the activity of the
descending antinociceptive system and have a synergistic
effect with opioid analgesics. In addition to the potentialisa-
tion of the analgesic effect of opioids, they also have
myorelaxant and anxiolytic effects, particularly serotonin
reuptake inhibitors. Inhibition of serotonin and norepineph-
rine reuptake from the synaptic cleft, in addition to having
inhibitory effect on nociception processes in the spinal cord,
also has an inhibitory effect on sodium channels and the
processes of NMDA receptors activation.
In the management of neuropathic pain, effectiveness has
been documented in the case of TCAs (amitriptyline, desipra-
mine, imipramine, nortriptyline) and SNRIs (duloxetine,
venlafaxine). Other frequently used antidepressants, such as
SSRIs or mianserine, do not have such an effect; research
results are either controversial or negative. Nevertheless, they
may be used in speciﬁc pain syndromes, e.g. drugs from the
SSRI class in the treatment of some central neuropathic pain
syndromes. Mianserine and mirtazapine may be used as
adjuvants for potentialisation of opioid analgesia.
TCAs are not sufﬁciently effective in the management of
HIV-associated neuropathy, chemotherapy-induced periph-
eral neuropathy or radiculopathy after failed back surgery
[5,24,25]. Amitriptyline should be used with caution in elderly
patients with a cardiovascular disease or narrow angle
glaucoma and in men with prostate gland hypertrophy. What
may also be a problem is the TCA-induced sedation and highimportant contraindications for first-line drugs for the
Maximum daily dose Precautions or
contraindications
150 mg Substantial anticholinergic
effects
120 mg Not to be used in patients
with glaucoma
225 mg Dose adjustment in
patients with renal failure
is necessary
600 mg in two divided
doses
Caution should be
exercised when used in
patients with renal failure
3600 mg in three divided
doses
Dose should be reduced
in patients with impaired
renal function
Maximum 3 TTSs for
12–18 h/day
Local hypersensitivity
reactions are possible
400 mg/day in divided
doses; 300 mg/day in
patients aged over
75 years
Caution should be exercised
when used in patients with
renal failure
l
There is no maximum
dose
Possible gastrointestinal
dysfunction, prevention of
constipation is necessary
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patients with cardiovascular diseases, the daily dose of
amitriptyline should not exceed 100 mg.
Of the SNRI class, venlafaxine and duloxetine are used.
They are effective in the management of peripheral neuro-
pathic pain, low back pain syndromes, brachial pain and
ﬁbromyalgia (level 1 evidence according to EBM) [23]. Drugs
from the SNRI class are characterised by favourable safety
proﬁle compared with TCAs. Patients treated with SNRI may
have elevated blood pressure. In about 15% of patients, sleep
disorders may develop. SNRIs should be used with caution in
patients with cardiovascular diseases.
12. Anticonvulsants
The mechanism of action of this class of drugs consists in the
inhibition of neuronal hyperexcitability occurring in neuro-
pathic pain, just as in epilepsy. Anticonvulsants are char-
acterised by varied chemical composition and varied
pharmacodynamic effects, which translates into their effec-
tiveness in the management of neuropathic pain. The cellular
mechanism of action of this class of drugs consists in the
reduction in the concentration of sodium and/or calcium ions
in neurons. The drugs potentate the processes of pre- and
postsynaptic inhibition in the central nervous system struc-
tures.
Due to their high effectiveness and the safety proﬁle in the
management of neuropathic pain, drugs acting on the calcium
channel a-2-d subunit, i.e. pregabalin and gabapentin, are used
most frequently. Despite similar mechanism of action, their
effectiveness in the treatment of neuropathic pain may vary;
lack of effectiveness of one drug can indicate the need for
administration of another.
The effectiveness in the treatment of diabetic neuropathy
and peripheral neuropathy has been shown for gabapentin
(level 1 according to EBM) [21,23,30]. Treatment with gaba-
pentin should be started with the lowest dose of 100 mg which
should be systematically titrated upwards to 3600 mg/day
until the expected analgesic effect is achieved. Typically,
higher doses are effective. The most common adverse effect of
gabapentin include excessive sedation, dizziness and gait
instability.
The effectiveness of pregabalin was shown for post-
herpetic neuralgia, diabetic neuropathy, trigeminal neuralgia,
chronic post-surgical pain and lower back pain (level 1
according to EBM) [21,23,30]. The recommended dosage is
150–600 mg/day. Pregabalin does not interact with concomi-
tant medications. Of the most common adverse effects,
peripheral oedema, excessive sedation and dizziness should
be listed.
What is characteristic for pregabalin is its linear pharma-
cokinetics which makes the relationship between the dose and
the effectiveness more evident and predictable. Also, there are
no clinically signiﬁcant interactions with other drugs, which
allows using it in patients with numerous comorbidities,
unlike gabapentin. Pregabalin is the treatment of choice in
elderly patients with neuropathic pain due to insigniﬁcant risk
of inducing adverse reactions and in patients with cancer-
related neuropathic pain.Of other anticonvulsants, carbamazepine is used for the
management of trigeminal neuralgia. Due to many years of
experience, it is the ﬁrst-line drug in this indication. The
treatment should be started with low doses administered
once or twice daily, and the doses should gradually be
titrated upwards. In the case of no effectiveness or intense
adverse effects after carbamazepine, oxcarbazepine at
300–3000 mg per day is recommended. In terms of potency
of effect, 200 mg of carbamazepine is equivalent to 300 mg of
oxcarbazepine. Adverse effects (liver damage, hyponatrae-
mia) of oxcarbazepine are less common compared with
carbamazepine.
Lamotrigine, an inhibitor of slow type IIA sodium channels,
shows effectiveness in both peripheral neuropathic pain and
central pain (level 1 according to EBM). Lamotrigine potenti-
ates the effect of carbamazepine. However, when both drugs
are combined, an increased risk of the Stevens-Johnson
syndrome should be borne in mind. Treatment with lamo-
trigine is started with 50 mg on day 1, then the dose is
increased to 100 mg on day 2, and 300 mg on day 3. On day 4,
the dose of 400 mg is administered and then maintained as the
therapeutic dose.
Valproic acid, which acts by the GABA-ergic system and by
the inhibition of neuronal calcium and sodium channels,
shows effectiveness in peripheral neuropathies, migraine and
cluster headache and central pain (level 2 evidence according
to EBM). Treatment is started with 300 mg, preferably
administered at bedtime, and then the dose is increased
every 3 days up to the maximum dose of 1500 mg/day. The
most common adverse effects include sedation and hair loss.
Hepatotoxicity may also occur, therefore long-term therapy
necessitates monitoring of the liver function.
13. Opioid analgesics
Double-blind randomised clinical trials have shown that
opioid analgesics have similar efﬁcacy as gabapentin and
TCAs in the treatment of neuropathic pain [5,21,23–25,30].
Weak opioids are less frequently used; usually in patients with
moderate neuropathic pain or in elderly patients who are at a
greater risk of developing adverse reactions to strong opioids.
Due to its mechanism of action, tramadol may be treated as a
weak opioid and recommended for the management of mild to
moderate neuropathic pain and for the treatment of elderly
patients [32].
The group of strong opioids recommended for the
management of moderate to severe pain and available in
Poland includes: morphine, oxycodone, fentanyl, buprenor-
phine and methadone. The choice of an opioid is not easy for
several reasons. So far, no controlled clinical trials comparing
various opioids have been conducted in patients with cancer-
related neuropathic pain. Furthermore, published systematic
reviews do not indicate unambiguously which opioid is the
most effective in patients with neuropathic pain. Due to their
mechanism of action, buprenorphine (antihyperalgesic effect)
and methadone (in addition to the opioid component, the drug
blocks NMDA receptors and increases the norepinephrine and
serotonin concentration) appear to be the preferred opioids. In
future, the use of tapentadol, which in addition to an opioid
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also prove interesting [33].
Another option involves the concomitant use of two or
more opioids, although no clear recommendations are
available [34]. Typically, an opioid is combined with adjuvant
analgesics, i.e. antidepressants and anticonvulsants. During
treatment with opioids, possible adverse effects (e.g. consti-
pation) should be borne in mind and prevented. Also, the
consumption of medication should be monitored to prevent
dependence, the risk of which is negligible if the treatment
regimen is complied with.
14. Topical medication
Topical lidocaine acts primarily on voltage-gated pathological
sodium channels in the damaged nerve, which initiate
repeated ectopic excitations. The other mechanism of action
of lidocaine is connected with the inhibition of the release of
nociceptive mediators by keratinocytes, which account for 95%
of epidermal cells and which are closely connected with nerve
ﬁbres. Lidocaine in the form of patches has an additional
cooling effect on the skin (the patch is at the same time a
hydrogel dressing) and provides disease-affected skin with
mechanical protection [35,36].
5% lidocaine patches applied to the skin is recommended
as the ﬁrst-line treatment for localised peripheral neuro-
pathic pain, alone or in combination with another ﬁrst-line
drug. NNT for 5% lidocaine in post-herpetic neuralgia is
rated at 4.4 [5,30,37,38]. Published in 2009 metaanalysis of
six databases (32 studies, 38 publications) showed that 5%
lidocaine is effective in the management of post-herpetic
neuralgia (level 1 evidence according to EBM), and in painful
diabetic neuropathy its effectiveness is similar to that of
amitriptyline, capsaicin, gabapentin and pregabalin [38].
However, the use of 5% lidocaine, compared with the above-
mentioned drugs, is associated with fewer and less clinically
signiﬁcant adverse effects. The most common adverse effect
is local skin irritation [39]. Furthermore, positive effects
of 5% lidocaine have also been observed in intercostal
neuralgia, chronic post-surgical pain (thoracotomy, mastec-
tomy, inguinal hernia surgery, amputation) and meralgia
paraesthetica [38].
Capsaicin is a highly selective vanilloid receptor agonist
from the group of transient receptor potential vanilloid 1
(TRPV1) [40]. The mechanism of action of capsaicin consists in
causing depletion of the neurotransmitter substance P from
nerve ﬁbre terminals. This results in reversible depletion of
substance P supplies and reduction in pain transmission from
the periphery to the higher layers of the central nervous
system. However, the basic mechanism of action of 8%
capsaicin primarily results from ion channels opening to
calcium ions conjugated with TPRV1 receptor, which in turn
results in defunctionalisation (atrophy) of primary nerve
endings following reversible mitochondrial damage.
8% capsaicin patches have been available in Poland since
2009. The last review of the Cochrane Collaboration analysed
the data from six studies involving 2073 participants compar-
ing the results of 8% to the 0.04% (control group) topical
capsaicin in post herpetic and HIV neuropathic pain. Thehighest rates of pain relief for 2–12 weeks were seen where
capsaicin was applied for 60 min. The effectiveness of the high
concentration of topical capsaicin is similar to the other drugs
in chronic neuropathic pain [41].
15. NMDA receptor antagonists
Overexcitability of the NMDA receptor may be a cause of the
central sensitisation phenomenon. To reduce the increased
activity of the NMDA receptor, ketamine and dextromethor-
phan are used.
Ketamine is administered orally at 20–40 mg 4–6 times/day,
epidurally at 30 mg or intravenously by a continuous infusion
at 1–2 mg/kg b.w./min. Dextromethorphan, which may be used
in both diabetic and post-herpetic neuropathy, is administered
in 2–3 oral doses of 45 mg [23,30].
16. Management of neuropathic pain –
recommendations
1. Pain management should be preceded by establishing the
cause of neuropathic pain (e.g. diabetes mellitus) and
starting an appropriate treatment (e.g. anti-diabetic treat-
ment), if possible.
2. Prior to the initiation of pain treatment, relevant comorbid-
ities (e.g. depression, cardiac or renal diseases) should be
identiﬁed as they may constitute contraindications for
treatment or necessitate analgesic dosage adjustment.
3. The patient should be informed about the diagnosis and
treatment plan and should understand the need to hold
realistic expectations about treatment effectiveness.
4. Speciﬁc neuropathic pain syndromes should be managed in
accordance with the current recommendations related to
these syndromes.
5. First-line drugs for neuropathic pain include:
- TCAs or SNRIs (venlafaxine or duloxetine)
- pregabalin or gabapentin
- topical lidocaine
- opioid analgesics or tramadol.
6. If the ﬁrst-line treatment is effective (at least 50% pain
reduction), it should be continued for adequate time. If the
effectiveness is inadequate, another ﬁrst-line drug should
be added. If the ﬁrst-line drug is not effective, it should be
replaced with another ﬁrst-line drug.
7. Lack of effectiveness of ﬁrst-line drugs, used at adequate
doses either alone or in combination, indicates the need for
attempting treatment with second-line and third-line
drugs.
8. Pharmacologic management should be complemented with
non-pharmacologic modalities, if possible.
9. Treatment effectiveness should be assessed with appropri-
ate frequency.
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